Thadani Udho, Ripley Toni L
University of Oklahoma Health Sciences Center, Cardiovascular Section, Department of Medicine, Oklahoma City, OK 73104, USA.
Expert Opin Drug Saf. 2007 Jul;6(4):385-96. doi: 10.1517/14740338.6.4.385.
Nitrates are potent venous dilators and anti-ischemic agents. They are widely used for the relief of chest pain and pulmonary congestion in patients with acute coronary syndromes and heart failure. Nitrates, however, do not reduce mortality in patients with acute coronary syndromes. Combination of nitrates and hydralazine when given in addition to beta-blockers and angiotensin-converting enzyme (ACE) inhibitors reduce mortality and heart failure hospitalizations in patients with heart failure due to left ventricular systolic dysfunction who are of African-American origin. Side effects during nitrate therapy are common but are less well described in the literature compared with the reported side effects in patients with stable angina pectoris. The reported incidence of side effects varies highly among different studies and among various disease states. Headache is the most commonly reported side effect with an incidence of 12% in acute heart failure, 41-73% in chronic heart failure, 3-19% in unstable angina and 2-26% in acute myocardial infarction. The reported incidence of hypotension also differs: 5-10% in acute heart failure, 20% in chronic heart failure, 9% in unstable angina and < 1-48% in acute myocardial infarction, with the incidence being much higher with concomitant nitrate therapy plus angiotensin-converting enzyme inhibitors. Reported incidence of dizziness is as low as 1% in patients with acute myocardial infarction to as high as 29% in patients with heart failure. Severe headaches and/or symptomatic hypotension may necessitate discontinuation of nitrate therapy. Severe life threatening hypotension or even death may occur when nitrates are used in patients with acute inferior myocardial infarction associated with right ventricular dysfunction or infarction, or with concomitant use of phosphodiesterase-5 inhibitors or N-acetylcysteine. Despite the disturbing observational reports in the literature that continuous and prolonged use of nitrates may lead to increased mortality and recurrent myocardial infarction in patients with stable coronary artery disease, no such adverse effects of nitrates have been reported in the large randomized trials in patients with acute myocardial infarction or chronic heart failure.
硝酸盐是强效的静脉扩张剂和抗缺血药物。它们广泛用于缓解急性冠状动脉综合征和心力衰竭患者的胸痛及肺充血。然而,硝酸盐并不能降低急性冠状动脉综合征患者的死亡率。对于非洲裔美国裔、因左心室收缩功能障碍导致心力衰竭的患者,在使用β受体阻滞剂和血管紧张素转换酶(ACE)抑制剂的基础上加用硝酸盐和肼屈嗪,可降低死亡率并减少心力衰竭住院次数。硝酸盐治疗期间的副作用很常见,但与稳定型心绞痛患者报告的副作用相比,在文献中的描述较少。不同研究以及不同疾病状态下报告的副作用发生率差异很大。头痛是最常报告的副作用,在急性心力衰竭中的发生率为12%,慢性心力衰竭中为41 - 73%,不稳定型心绞痛中为3 - 19%,急性心肌梗死中为2 - 26%。报告的低血压发生率也有所不同:急性心力衰竭中为5 - 10%,慢性心力衰竭中为20%,不稳定型心绞痛中为9%,急性心肌梗死中为<1 - 48%,在硝酸盐治疗联合血管紧张素转换酶抑制剂时发生率更高。报告的头晕发生率在急性心肌梗死患者中低至1%,在心力衰竭患者中高达29%。严重头痛和/或症状性低血压可能需要停用硝酸盐治疗。当硝酸盐用于伴有右心室功能障碍或梗死的急性下壁心肌梗死患者,或与磷酸二酯酶-5抑制剂或N - 乙酰半胱氨酸同时使用时,可能会发生严重的危及生命的低血压甚至死亡。尽管文献中有令人不安的观察报告称,持续和长期使用硝酸盐可能会导致稳定型冠状动脉疾病患者死亡率增加和心肌梗死复发,但在急性心肌梗死或慢性心力衰竭患者的大型随机试验中,尚未报告硝酸盐有此类不良反应。